PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

Antonio Russo, Anna Maria Frezza, Fotios Loupakis, Alice Zoccoli, Andrea Onetti Muda, Giuseppe Perrone, Gaia Schiavon, Anna Maria Ruzzo, Sara Galluzzo, Pierfilippo Crucitti, Carla Rabitti, Bruno Vincenzi, Alfredo Falcone, Francesco Graziano, Giuseppe Tonini, Daniele Santini, Sergio Rizzo

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy.EXPERIMENTAL DESIGN:74 metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry.RESULTS:PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P < 0.0001). A statistical significant difference was also detected in OS (15.6 and 24.5 months respectively, P = 0.003). The impact of PML down-regulation on TTP and OS was statistically significant also in a multivariate model.CONCLUSIONS:This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy.
Lingua originaleEnglish
pagine (da-a)927-933
Numero di pagine7
RivistaJournal of Cellular Physiology
Volume227
Stato di pubblicazionePublished - 2012

Fingerprint

oxaliplatin
Chemotherapy
Colorectal Neoplasms
Drug Therapy
Down-Regulation
Antineoplastic Agents
Apoptosis
Carcinogenesis
Therapeutics
Retrospective Studies
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cita questo

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. / Russo, Antonio; Frezza, Anna Maria; Loupakis, Fotios; Zoccoli, Alice; Muda, Andrea Onetti; Perrone, Giuseppe; Schiavon, Gaia; Ruzzo, Anna Maria; Galluzzo, Sara; Crucitti, Pierfilippo; Rabitti, Carla; Vincenzi, Bruno; Falcone, Alfredo; Graziano, Francesco; Tonini, Giuseppe; Santini, Daniele; Rizzo, Sergio.

In: Journal of Cellular Physiology, Vol. 227, 2012, pag. 927-933.

Risultato della ricerca: Article

Russo, A, Frezza, AM, Loupakis, F, Zoccoli, A, Muda, AO, Perrone, G, Schiavon, G, Ruzzo, AM, Galluzzo, S, Crucitti, P, Rabitti, C, Vincenzi, B, Falcone, A, Graziano, F, Tonini, G, Santini, D & Rizzo, S 2012, 'PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients', Journal of Cellular Physiology, vol. 227, pagg. 927-933.
Russo, Antonio ; Frezza, Anna Maria ; Loupakis, Fotios ; Zoccoli, Alice ; Muda, Andrea Onetti ; Perrone, Giuseppe ; Schiavon, Gaia ; Ruzzo, Anna Maria ; Galluzzo, Sara ; Crucitti, Pierfilippo ; Rabitti, Carla ; Vincenzi, Bruno ; Falcone, Alfredo ; Graziano, Francesco ; Tonini, Giuseppe ; Santini, Daniele ; Rizzo, Sergio. / PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. In: Journal of Cellular Physiology. 2012 ; Vol. 227. pagg. 927-933.
@article{617b42e16cab43388db19bd96c1783a2,
title = "PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients",
abstract = "PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy.EXPERIMENTAL DESIGN:74 metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry.RESULTS:PML down-regulation was detected in 39 (52.7{\%}) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6{\%}) in patients with PML down-regulation than in patients with preserved PML expression (60{\%}) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P < 0.0001). A statistical significant difference was also detected in OS (15.6 and 24.5 months respectively, P = 0.003). The impact of PML down-regulation on TTP and OS was statistically significant also in a multivariate model.CONCLUSIONS:This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy.",
author = "Antonio Russo and Frezza, {Anna Maria} and Fotios Loupakis and Alice Zoccoli and Muda, {Andrea Onetti} and Giuseppe Perrone and Gaia Schiavon and Ruzzo, {Anna Maria} and Sara Galluzzo and Pierfilippo Crucitti and Carla Rabitti and Bruno Vincenzi and Alfredo Falcone and Francesco Graziano and Giuseppe Tonini and Daniele Santini and Sergio Rizzo",
year = "2012",
language = "English",
volume = "227",
pages = "927--933",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

AU - Russo, Antonio

AU - Frezza, Anna Maria

AU - Loupakis, Fotios

AU - Zoccoli, Alice

AU - Muda, Andrea Onetti

AU - Perrone, Giuseppe

AU - Schiavon, Gaia

AU - Ruzzo, Anna Maria

AU - Galluzzo, Sara

AU - Crucitti, Pierfilippo

AU - Rabitti, Carla

AU - Vincenzi, Bruno

AU - Falcone, Alfredo

AU - Graziano, Francesco

AU - Tonini, Giuseppe

AU - Santini, Daniele

AU - Rizzo, Sergio

PY - 2012

Y1 - 2012

N2 - PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy.EXPERIMENTAL DESIGN:74 metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry.RESULTS:PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P < 0.0001). A statistical significant difference was also detected in OS (15.6 and 24.5 months respectively, P = 0.003). The impact of PML down-regulation on TTP and OS was statistically significant also in a multivariate model.CONCLUSIONS:This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy.

AB - PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy.EXPERIMENTAL DESIGN:74 metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry.RESULTS:PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P < 0.0001). A statistical significant difference was also detected in OS (15.6 and 24.5 months respectively, P = 0.003). The impact of PML down-regulation on TTP and OS was statistically significant also in a multivariate model.CONCLUSIONS:This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy.

UR - http://hdl.handle.net/10447/77113

M3 - Article

VL - 227

SP - 927

EP - 933

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -